STOCK TITAN

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags

Altamira Therapeutics (Nasdaq: CYTO) has announced the pricing of a public offering to raise up to $12 million. The offering includes 5,555,556 common shares (or pre-funded warrants) with accompanying Series A-1 and A-2 common warrants, priced at $0.72 per share. The initial gross proceeds are expected to be $4 million, with potential additional proceeds of $8 million if all warrants are exercised. The funds will be used for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close around September 19, 2024. Additionally, certain existing warrants will be amended to reduce the exercise price from $9.00 to $0.72 per common share.

Altamira Therapeutics (Nasdaq: CYTO) ha annunciato il prezzo di un'offerta pubblica per raccogliere fino a $12 milioni. L'offerta comprende 5.555.556 azioni ordinarie (o warrant prefinanziati) con relativi warrant di Serie A-1 e A-2, con un prezzo di $0.72 per azione. Si prevede che i proventi lordi iniziali siano di $4 milioni, con possibili proventi aggiuntivi di $8 milioni se tutti i warrant vengono esercitati. I fondi saranno utilizzati per capitale circolante e scopi aziendali generali. H.C. Wainwright & Co. funge da agente di collocamento esclusivo. Si prevede che l'offerta si concluda intorno al 19 settembre 2024. Inoltre, alcuni warrant esistenti saranno modificati per ridurre il prezzo di esercizio da $9.00 a $0.72 per azione ordinaria.

Altamira Therapeutics (Nasdaq: CYTO) ha anunciado el precio de una oferta pública para recaudar hasta $12 millones. La oferta incluye 5,555,556 acciones ordinarias (o warrants prefinanciados) junto con warrants de la Serie A-1 y A-2, con un precio de $0.72 por acción. Se espera que los ingresos brutos iniciales sean de $4 millones, con la posibilidad de ingresos adicionales de $8 millones si se ejercen todos los warrants. Los fondos se utilizarán para capital de trabajo y propósitos corporativos generales. H.C. Wainwright & Co. actúa como el agente de colocación exclusivo. Se espera que la oferta cierre alrededor del 19 de septiembre de 2024. Además, ciertos warrants existentes serán enmendados para reducir el precio de ejercicio de $9.00 a $0.72 por acción ordinaria.

Altamira Therapeutics (Nasdaq: CYTO)는 최대 $12 백만을 모금하기 위한 공모 가격을 발표했습니다. 이 오퍼링에는 5,555,556 보통주 (또는 사전 자금 조달 워런트)와 함께 A-1 및 A-2 시리즈 보통 워런트가 포함되어 있으며, 주당 $0.72로 가격이 책정되었습니다. 초기 총 수익은 $4 백만이 예상되며, 모든 워런트가 행사될 경우 추가로 $8 백만이 발생할 수 있습니다. 자금은 운전 자본 및 일반 기업 목적에 사용될 것입니다. H.C. Wainwright & Co.는 독점적인 배치 에이전트로 활동하고 있습니다. 이 오퍼링은 2024년 9월 19일경에 마감될 것으로 예상됩니다. 또한, 기존의 몇몇 워런트는 행사 가격을 $9.00에서 보통주당 $0.72로 줄이기 위해 수정될 것입니다.

Altamira Therapeutics (Nasdaq: CYTO) a annoncé le prix d'une offre publique pour lever jusqu'à $12 millions. L'offre comprend 5.555.556 actions ordinaires (ou warrants préfinancés) avec les warrants ordinaires de série A-1 et A-2, fixés à $0.72 par action. Les premiers produits bruts devraient s'élever à $4 millions, avec des produits supplémentaires potentiels de $8 millions si tous les warrants sont exercés. Les fonds seront utilisés pour le fonds de roulement et les besoins généraux de l'entreprise. H.C. Wainwright & Co. agit en tant qu'agent de placement exclusif. L'offre devrait se clôturer autour du 19 septembre 2024. De plus, certains warrants existants seront modifiés pour réduire le prix d'exercice de $9.00 à $0.72 par action ordinaire.

Altamira Therapeutics (Nasdaq: CYTO) hat die Preisgestaltung einer öffentlichen Angebotsaktion zur Beschaffung von bis zu $12 Millionen bekannt gegeben. Das Angebot umfasst 5.555.556 Stammaktien (oder vorfinanzierte Warrants) mit begleitenden Series A-1 und A-2 Stammwarrants, die zu einem Preis von $0.72 pro Aktie angeboten werden. Die anfänglichen Bruttoeinnahmen werden auf $4 Millionen geschätzt, mit möglichen zusätzlichen Einnahmen von $8 Millionen, wenn alle Warrants ausgeübt werden. Die Mittel werden für Betriebskapital und allgemeine Unternehmenszwecke verwendet. H.C. Wainwright & Co. fungiert als exklusiver Platzierungsagent. Der Abschluss des Angebots wird für etwa den 19. September 2024 erwartet. Zudem werden bestimmte bestehende Warrants geändert, um den Ausübungspreis von $9.00 auf $0.72 pro Stammaktie zu senken.

Positive
  • Potential to raise up to $12 million in total gross proceeds
  • Initial gross proceeds of $4 million with additional $8 million possible from warrant exercises
  • Funds to be used for working capital and general corporate purposes
  • Reduced exercise price for existing warrants from $9.00 to $0.72 per common share
Negative
  • Potential dilution for existing shareholders due to the issuance of new shares and warrants
  • Offering price of $0.72 per share may indicate a discount to current market price
  • No guarantee that the additional $8 million from warrant exercises will be realized

Insights

This $4 million public offering with potential for an additional $8 million through warrant exercises is a significant move for Altamira Therapeutics. The pricing at $0.72 per share represents a substantial discount, indicating potential dilution for existing shareholders. The two-tiered warrant structure tied to specific milestones is intriguing, potentially incentivizing investors while aligning their interests with the company's progress.

The amendment of existing warrants from $9.00 to $0.72 exercise price is notable, suggesting the company's struggle to maintain its stock price. This offering appears to be a desperate attempt to raise capital, possibly due to cash burn or upcoming expenses. Investors should closely monitor Altamira's cash position and burn rate in upcoming financial reports.

Altamira's focus on RNA delivery technology beyond the liver is promising, but this offering raises concerns about the company's financial health. The mention of AM-401 and AM-411 nanoparticles in the warrant terms suggests these are key programs to watch. The milestone-linked warrants tied to biodistribution data and commercialization agreements indicate potential near-term catalysts.

However, the need for immediate capital through a discounted offering might signal delays or setbacks in their pipeline. Investors should scrutinize upcoming data releases and partnership announcements, as these could significantly impact the company's valuation and trigger warrant exercises. The success of this financing strategy heavily depends on positive clinical developments in the next 18 months to 5 years.

Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) --

  • $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked warrants

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the pricing of a public offering of an aggregate of 5,555,556 common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5,555,556 common shares and Series A-2 common warrants to purchase up to 5,555,556 common shares, at a combined public offering price of $0.72 per share (or per pre-funded warrant in lieu thereof) and accompanying Series A-1 common warrant and Series A-2 common warrant. The Series A-1 common warrants will have an exercise price of $0.72 per share, will be immediately exercisable upon issuance and will expire on the earlier of the eighteen-month anniversary of the initial issuance date or 60 days following the date the Company publicly announces positive biodistribution data for AM-401 or AM-411 nanoparticles. The Series A-2 common warrants will have an exercise price of $0.72 per share, will be immediately exercisable upon issuance and will expire on the earlier of the five-year anniversary of the initial issuance date or six months following the date the Company publicly announces the entry into one or more agreements relating to the further development and commercialization for AM-401 or AM-411, provided at least one such agreement covers a territory that includes all or a part of the European Union or the United States. The closing of the offering is expected to occur on or about September 19, 2024, subject to the satisfaction of customary closing conditions. 

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from this offering are expected to be approximately $4.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Series A-1 common warrants and Series A-2 common warrants, if fully exercised on a cash basis, will be approximately $8.0 million. No assurance can be given that any of the Series A-1 common warrants or Series A-2 common warrants will be exercised. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The securities described above are being offered pursuant to a registration statement on Form F-1 (File No. 333-281724), as amended, originally filed on August 22, 2024 with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on September 17, 2024. The offering is being made only by means of a prospectus which forms a part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC and a final prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC's website at http://www.sec.gov and may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

The Company also has agreed that certain existing warrants to purchase up to an aggregate of 555,556 common shares that were previously issued in July 2023 at an exercise price of $9.00 per common share and an expiration date of July 10, 2028 will be amended effective upon the closing of the offering such that the amended warrants will have a reduced exercise price of $0.72 per common share and will expire five years following the closing of the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Altamira Therapeutics

Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/   

Forward-Looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira’s strategies or expectations and statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the anticipated use of proceeds therefrom, the ability of the Company to achieve certain milestone events, and the exercise of the Series A-1 common warrants and Series A-2 common warrants upon the achievement of such milestone events or otherwise prior to their expiration. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, market and other conditions, the clinical utility of Altamira’s product candidates, the timing or likelihood of regulatory filings and approvals, Altamira’s intellectual property position and Altamira’s financial position. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira’s Annual Report on Form 20-F for the year ended December 31, 2023, and in Altamira’s other filings with the SEC, which are available free of charge on the SEC’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

CONTACT:

Hear@altamiratherapeutics.com



FAQ

What is the total amount Altamira Therapeutics (CYTO) aims to raise in this public offering?

Altamira Therapeutics (CYTO) aims to raise up to $12 million in total, with $4 million in initial gross proceeds and potential additional proceeds of $8 million if all warrants are exercised.

When is the expected closing date for Altamira Therapeutics' (CYTO) public offering?

The public offering is expected to close on or about September 19, 2024, subject to customary closing conditions.

What is the pricing of Altamira Therapeutics' (CYTO) public offering?

The public offering is priced at $0.72 per common share (or pre-funded warrant) with accompanying Series A-1 and A-2 common warrants.

How does Altamira Therapeutics (CYTO) plan to use the proceeds from this offering?

Altamira Therapeutics (CYTO) intends to use the net proceeds from this offering for working capital and general corporate purposes.

Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda)

NASDAQ:CYTO

CYTO Rankings

CYTO Latest News

CYTO Stock Data

1.68M
3.76M
0.53%
3.14%
0.82%
Biotechnology
Healthcare
Link
United States of America
Hamilton